Search

Your search keyword '"Dally, Najib"' showing total 171 results
Start Over Author "Dally, Najib"
171 results on '"Dally, Najib"'

1. Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study

Author

Adarraga, María Dolores, Conesa, Ana Alberich, Aibar, Jesús, Lozano, Alicia Alda, Alfonso, Joaquín, Carrillo, Jesús Alonso, Amado, Cristina, García, María Angelina, Arcelus, Juan Ignacio, Ballaz, Aitor, Barba, Raquel, Hernando, María Barca, Barbagelata, Cristina, Barrón, Manuel, Andrés, Belén Barrón, Chaib, Fahd Beddar, Blanco Molina, María Ángeles, Caballero, Juan Carlos, Castellanos, Gonzalo, Chasco, Leyre, Criado, Juan, de Ancos, Cristina, Toro, Jorge del, Rodríguez, Pablo Demelo, de Juana Izquierdo, Cristina, Díaz Brasero, Ana María, Díaz Peromingo, José Antonio, Silva, Álvaro Dubois, Escribano, Juan Carlos, Falgá, Concepción, Farfán Sedano, Ana Isabel, Aracil, Cleofe Fernández, Capitán, Carmen Fernández, Jiménez, Begoña Fernández, Fernández Reyes, José Luis, Fidalgo, María Ángeles, Francisco, Iria, Gabara, Cristina, Valle, Francisco Galeano, Bragado, Francisco García, Ortega, Alberto García, Sebastián, Olga Gavín, Gil de Gómez, María Allende, Díaz, Aída Gil, Cuervo, Covadonga Gómez, Munera, Adriana González, Grau, Enric, Guirado, Leticia, Gutiérrez, Javier, Blasco, Luis Hernández, Palomares, Luis Jara, Jaras, María Jesús, Jiménez, David, Jiménez, Rafael, Jou, Inés, Joya, María Dolores, Justo, Sara Lainez, Lalueza, Antonio, Lecumberri, Ramón, León Ramírez, José Manuel, Llamas, Pilar, Lobo, José Luis, Jiménez, Luciano López, Miguel, Patricia López, López Núñez, Juan José, Ruiz, Antonio López, López Sáez, Juan Bosco, Lorenzo, Alicia, Lumbierres, Marina, Madridano, Olga, Maestre, Ana, Marchena, Pablo Javier, Marcos, María, Martín del Pozo, Mar, Martos, Francisco Martín, Maza, Jorge Manuel, Mena, Elisabeth, Mercado, Maria Isabel, Moisés, Jorge, Monreal, Manuel, Morales, María del Valle, Navas, Maria Sierra, Nieto, José Antonio, Núñez Fernández, Manuel Jesús, Olid, Mónica, Ortega, Lucía Ordieres, Ortiz, María, Osorio, Jeisson, Otálora, Sonia, Otero, Remedios, Gómez, Nazaret Pacheco, Pagán, Javier, Palomeque, Andrea Catalina, Paredes, Ezequiel, Caballero, Pedro Parra, Pedrajas, José María, Ductor, Cristina Pérez, Pinar, Montserrat Pérez, Peris, María Luisa, Pesce, María Lourdes, Porras, José Antonio, Puchades, Ramón, Cívico, Francisco Rivera, Cobo, Ana Rodríguez, Rosa, Vladimir, Brugera, Marta Romero, Artacho, Pedro Ruiz, Giménez, Nuria Ruiz, Ruiz, Justo Ruiz, Salgueiro, Georgina, Sancho, Teresa, Sendín, Vanesa, Sigüenza, Patricia, Soler, Silvia, Fernández, Susana Suárez, Tirado, Raimundo, Vilar, Ana Torrents, Torres, María Isabel, Santos, Javier Trujillo, Uresandi, Fernando, Valle, Reina, Varona, José Felipe, Villalobos, Aurora, Villares, Paula, Ay, Cihan, Nopp, Stephan, Pabinger, Ingrid, Engelen, Matthias, Vanassche, Thomas, Verhamme, Peter, Bok Yoo, Hugo Hyung, Montenegro, Ana Cristina, Morales, Silvia Natalia, Roa, Jairo, Hirmerova, Jana, Malý, Radovan, Bertoletti, Laurent, Bura-Riviere, Alessandra, Catella, Judith, Chopard, Romain, Couturaud, Francis, Espitia, Olivier, Grange, Claire, Leclercq, Barbara, Le Mao, Raphael, Mahé, Isabelle, Moustafa, Farès, Plaisance, Ludovic, Bartoli, Gabrielle Sarlon, Suchon, Pierre, Versini, Edouard, Schellong, Sebastian, Brenner, Benjamin, Dally, Najib, Tzoran, Inna, Sadeghipour, Parham, Rashidi, Fahrid, Abenante, Alessia, Barillari, Giovanni, Basaglia, Manuela, Bilora, Franca, Bissacco, Daniele, Bortoluzzi, Cristiano, Brandolin, Barbara, Casana, Renato, Ciammaichella, Maurizio, Colaizzo, Donatella, Dentali, Francesco, Di Micco, Pierpaolo, Grandone, Elvira, Imbalzano, Egidio, Deliliers, Daniela Lambertenghi, Negro, Federica, Pesavento, Raffaele, Poz, Alessandra, Prandoni, Paolo, Scarinzi, Paolo, Siniscalchi, Carmine, Taflaj, Beldisa, Tufano, Antonella, Visonà, Adriana, Hong, Ngoc Vo, Zalunardo, Beniamino, Skride, Andris, Kigitovica, Dana, Fonseca, Samuel, Marques, Rafael, Meireles, José, Pinto, Sara Barbosa, Bosevsky, Marijan, Eftimova, Aleksandra, Zdraveska, Marijan, Bounameaux, Henri, Mazzolai, Lucia, Aujayeb, Avinash, Bikdeli, Behnood, Caprini, Joseph, Weinberg, Ido, Bui, Hanh My, Jara-Palomares, Luis, Muriel, Alfonso, Demelo-Rodríguez, Pablo, López-Miguel, Patricia, López-Jiménez, Luciano, and Rivera-Cívico, Francisco

Published
2024
Full Text
View/download PDF

2. Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study

Author

Jara-Palomares, Luis, primary, Bikdeli, Behnood, additional, Jiménez, David, additional, Muriel, Alfonso, additional, Demelo-Rodríguez, Pablo, additional, Moustafa, Farès, additional, Villalobos, Aurora, additional, López-Miguel, Patricia, additional, López-Jiménez, Luciano, additional, Otálora, Sonia, additional, Peris, María Luisa, additional, Amado, Cristina, additional, Chopard, Romain, additional, Rivera-Cívico, Francisco, additional, Monreal, Manuel, additional, Adarraga, María Dolores, additional, Conesa, Ana Alberich, additional, Aibar, Jesús, additional, Lozano, Alicia Alda, additional, Alfonso, Joaquín, additional, Carrillo, Jesús Alonso, additional, García, María Angelina, additional, Arcelus, Juan Ignacio, additional, Ballaz, Aitor, additional, Barba, Raquel, additional, Hernando, María Barca, additional, Barbagelata, Cristina, additional, Barrón, Manuel, additional, Andrés, Belén Barrón, additional, Chaib, Fahd Beddar, additional, Blanco Molina, María Ángeles, additional, Caballero, Juan Carlos, additional, Castellanos, Gonzalo, additional, Chasco, Leyre, additional, Criado, Juan, additional, de Ancos, Cristina, additional, Toro, Jorge del, additional, Rodríguez, Pablo Demelo, additional, de Juana Izquierdo, Cristina, additional, Díaz Brasero, Ana María, additional, Díaz Peromingo, José Antonio, additional, Silva, Álvaro Dubois, additional, Escribano, Juan Carlos, additional, Falgá, Concepción, additional, Farfán Sedano, Ana Isabel, additional, Aracil, Cleofe Fernández, additional, Capitán, Carmen Fernández, additional, Jiménez, Begoña Fernández, additional, Fernández Reyes, José Luis, additional, Fidalgo, María Ángeles, additional, Francisco, Iria, additional, Gabara, Cristina, additional, Valle, Francisco Galeano, additional, Bragado, Francisco García, additional, Ortega, Alberto García, additional, Sebastián, Olga Gavín, additional, Gil de Gómez, María Allende, additional, Díaz, Aída Gil, additional, Cuervo, Covadonga Gómez, additional, Munera, Adriana González, additional, Grau, Enric, additional, Guirado, Leticia, additional, Gutiérrez, Javier, additional, Blasco, Luis Hernández, additional, Palomares, Luis Jara, additional, Jaras, María Jesús, additional, Jiménez, Rafael, additional, Jou, Inés, additional, Joya, María Dolores, additional, Justo, Sara Lainez, additional, Lalueza, Antonio, additional, Lecumberri, Ramón, additional, León Ramírez, José Manuel, additional, Llamas, Pilar, additional, Lobo, José Luis, additional, Jiménez, Luciano López, additional, Miguel, Patricia López, additional, López Núñez, Juan José, additional, Ruiz, Antonio López, additional, López Sáez, Juan Bosco, additional, Lorenzo, Alicia, additional, Lumbierres, Marina, additional, Madridano, Olga, additional, Maestre, Ana, additional, Marchena, Pablo Javier, additional, Marcos, María, additional, Martín del Pozo, Mar, additional, Martos, Francisco Martín, additional, Maza, Jorge Manuel, additional, Mena, Elisabeth, additional, Mercado, Maria Isabel, additional, Moisés, Jorge, additional, Morales, María del Valle, additional, Navas, Maria Sierra, additional, Nieto, José Antonio, additional, Núñez Fernández, Manuel Jesús, additional, Olid, Mónica, additional, Ortega, Lucía Ordieres, additional, Ortiz, María, additional, Osorio, Jeisson, additional, Otero, Remedios, additional, Gómez, Nazaret Pacheco, additional, Pagán, Javier, additional, Palomeque, Andrea Catalina, additional, Paredes, Ezequiel, additional, Caballero, Pedro Parra, additional, Pedrajas, José María, additional, Ductor, Cristina Pérez, additional, Pinar, Montserrat Pérez, additional, Pesce, María Lourdes, additional, Porras, José Antonio, additional, Puchades, Ramón, additional, Cívico, Francisco Rivera, additional, Cobo, Ana Rodríguez, additional, Rosa, Vladimir, additional, Brugera, Marta Romero, additional, Artacho, Pedro Ruiz, additional, Giménez, Nuria Ruiz, additional, Ruiz, Justo Ruiz, additional, Salgueiro, Georgina, additional, Sancho, Teresa, additional, Sendín, Vanesa, additional, Sigüenza, Patricia, additional, Soler, Silvia, additional, Fernández, Susana Suárez, additional, Tirado, Raimundo, additional, Vilar, Ana Torrents, additional, Torres, María Isabel, additional, Santos, Javier Trujillo, additional, Uresandi, Fernando, additional, Valle, Reina, additional, Varona, José Felipe, additional, Villares, Paula, additional, Ay, Cihan, additional, Nopp, Stephan, additional, Pabinger, Ingrid, additional, Engelen, Matthias, additional, Vanassche, Thomas, additional, Verhamme, Peter, additional, Bok Yoo, Hugo Hyung, additional, Montenegro, Ana Cristina, additional, Morales, Silvia Natalia, additional, Roa, Jairo, additional, Hirmerova, Jana, additional, Malý, Radovan, additional, Bertoletti, Laurent, additional, Bura-Riviere, Alessandra, additional, Catella, Judith, additional, Couturaud, Francis, additional, Espitia, Olivier, additional, Grange, Claire, additional, Leclercq, Barbara, additional, Le Mao, Raphael, additional, Mahé, Isabelle, additional, Plaisance, Ludovic, additional, Bartoli, Gabrielle Sarlon, additional, Suchon, Pierre, additional, Versini, Edouard, additional, Schellong, Sebastian, additional, Brenner, Benjamin, additional, Dally, Najib, additional, Tzoran, Inna, additional, Sadeghipour, Parham, additional, Rashidi, Fahrid, additional, Abenante, Alessia, additional, Barillari, Giovanni, additional, Basaglia, Manuela, additional, Bilora, Franca, additional, Bissacco, Daniele, additional, Bortoluzzi, Cristiano, additional, Brandolin, Barbara, additional, Casana, Renato, additional, Ciammaichella, Maurizio, additional, Colaizzo, Donatella, additional, Dentali, Francesco, additional, Di Micco, Pierpaolo, additional, Grandone, Elvira, additional, Imbalzano, Egidio, additional, Deliliers, Daniela Lambertenghi, additional, Negro, Federica, additional, Pesavento, Raffaele, additional, Poz, Alessandra, additional, Prandoni, Paolo, additional, Scarinzi, Paolo, additional, Siniscalchi, Carmine, additional, Taflaj, Beldisa, additional, Tufano, Antonella, additional, Visonà, Adriana, additional, Hong, Ngoc Vo, additional, Zalunardo, Beniamino, additional, Skride, Andris, additional, Kigitovica, Dana, additional, Fonseca, Samuel, additional, Marques, Rafael, additional, Meireles, José, additional, Pinto, Sara Barbosa, additional, Bosevsky, Marijan, additional, Eftimova, Aleksandra, additional, Zdraveska, Marijan, additional, Bounameaux, Henri, additional, Mazzolai, Lucia, additional, Aujayeb, Avinash, additional, Caprini, Joseph, additional, Weinberg, Ido, additional, and Bui, Hanh My, additional

Published
2024
Full Text
View/download PDF

3. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis

Author

Avivi, Irit, Perry, Chava, Segman, Yafit, Amit, Odelia, Bar-On, Yaeli, Katz, Ofrat Beyer, Gold, Ronit, Ribakovsky, Elena, Avigdor, Abraham, Vainstein, Vladimir, Goldschmidt, Neta, Ringelstein-Harlev, Shimrit, Horowitz, Netanel A., Gutwein, Odit, Gurion, Ronit, Itchaki, Gilad, Abadi, Uri, Nemets, Anatoly, Sofer, Orit, Vezker, Miri, Tadmor, Tamar, Dally, Najib, Filanovsky, Kalman, Leiba, Merav, Sarid, Nadav, Benyamini, Noam, Luttwak, Efrat, Herishanu, Yair, and Ram, Ron

Published
2022
Full Text
View/download PDF

5. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

Author

Schjesvold, Fredrik, Delimpasi, Sosana, Robak, Pawel, Coriu, Daniel, Nikolayeva, Anna, Tomczak, Waldemar, Pour, Ludek, Spicka, Ivan, Dimopoulos, Meletios-Athanasios, Masszi, Tamas, Doronin, Vadim, Minarik, Jiri, Salogub, Galina, Alekseeva, Yulia, Maisnar, Vladimir, Mikala, Gabor, Rosinol, Laura, Konstantinova, Tatiana, Lazzaro, Antonio, Liberati, Anna Marina, Symeonidis, Anargyros, Gatt, Moshe, Illes, Arpad, Abdulhaq, Haifaa, Dungarwalla, Moez, Grosicki, Sebastian, Hajek, Roman, Leleu, Xavier, Myasnikov, Alexander, Richardson, Paul G., Avivi, Irit, Deeren, Dries, Gironella, Mercedes, Hernandez-Garcia, Miguel Teodoro, Martinez Lopez, Joaquin, Newinger-Porte, Muriel, Ribas, Paz, Samoilova, Olga, Voog, Eric, Arnao-Herraiz, Mario, Carrillo-Cruz, Estrella, Corradini, Paolo, Dodlapati, Jyothi, Granell Gorrochategui, Miquel, Huang, Shang-Yi, Jenner, Matthew, Karlin, Lionel, Kim, Jin Seok, Kopacz, Agnieszka, Medvedeva, Nadezhda, Min, Chang-Ki, Mina, Roberto, Palk, Katrin, Shin, Ho-Jin, Sohn, Sang Kyun, Sonneveld, Pieter, Tache, Jason, Anagnostopoulos, Achilles, Arguiñano, Jose-Maria, Cavo, Michele, Filicko, Joanne, Garnes, Margaret, Halka, Janusz, Herzog-Tzarfati, Kathrin, Ipatova, Natalia, Kim, Kihyun, Krauth, Maria-Theresa, Kryuchkova, Irina, Lazaroiu, Mihaela Cornelia, Luppi, Mario, Proydakov, Andrei, Rambaldi, Alessandro, Rudzianskiene, Milda, Yeh, Su-Peng, Alcalá-Peña, Maria Magdalena, Alegre Amor, Adrian, Alizadeh, Hussain, Bendandi, Maurizio, Brearton, Gillian, Brown, Randall, Cavet, Jim, Dally, Najib, Egyed, Miklos, Hernández-Rivas, José Ángel, Kaare, Ain, Karsenti, Jean-Michel, Kloczko, Janusz, Kreisle, William, Lee, Je-Jung, Legiec, Wojciech, Machherndl-Spandl, Sigrid, Manda, Sudhir, Mateos, Maria-Victoria, Moiseev, Ivan, Moreb, Jan, Nagy, Zsolt, Nair, Santosh, Oriol-Rocafiguera, Albert, Osswald, Michael, Otero-Rodriguez, Paula, Peceliunas, Valdas, Plesner, Torben, Rey, Philippe, Rossi, Giuseppe, Stevens, Don, Suriu, Celia, Tarella, Corrado, Verlinden, Anke, Zannetti, Alain, Schjesvold, Fredrik H, Pour, Luděk, Špička, Ivan, Mikala, Gábor, Rosiñol, Laura, Symeonidis, Argiris, Moody, Victoria, Thuresson, Marcus, Byrne, Catriona, Harmenberg, Johan, Bakker, Nicolaas A, Hájek, Roman, and Richardson, Paul G

Published
2022
Full Text
View/download PDF

6. Clinical Significance and Outcome in Patients with Asymptomatic Versus Symptomatic Subsegmental Pulmonary Embolism

Author

Ana Rodríguez-Cobo, Carmen Fernández-Capitán, Yale Tung-Chen, Giorgina Salgueiro-Origlia, Aitor Ballaz, Cristiano Bortoluzzi, Gabrielle Sarlon-Bartoli, Maria Lourdes Pesce, Dally Najib, Manuel Monreal, and The RIETE Investigators

Subjects
pulmonary embolism, venous thrombosis, anticoagulants, bleeding, Medicine
Abstract

The clinical significance and optimal therapy of patients with subsegmental pulmonary embolism (SSPE) remain controversial. We used the data in the RIETE Registry to compare the baseline characteristics, treatment, and outcomes during anticoagulation and after its discontinuation in patients with asymptomatic vs. symptomatic SSPE. From January 2009 to September 2022, there were 2135 patients with a first episode of SSPE, of whom 160 (7.5%) were asymptomatic. Most patients in both subgroups received anticoagulant therapy (97% vs. 99.4%, respectively). During anticoagulation, 14 patients developed symptomatic pulmonary embolism (PE) recurrences, 28 lower-limb deep vein thrombosis (DVT), 54 bled, and 242 died. The patients with asymptomatic SSPE had similar rates of symptomatic PE recurrences (hazard ratio (HR): 2.46; 95% CI: 0.37–9.74), DVT (HR: 0.53; 95% CI: 0.03–2.80), or major bleeding (HR: 0.85; 95% CI: 0.21–2.42) to those with symptomatic SSPE, but had a higher mortality rate (HR: 1.59; 95% CI: 1.25–2.94). The rate of major bleeding outweighed the rate of PE recurrences (54 major bleeds vs. 14 PE recurrences), and the rate of fatal bleeds outweighed the rate of fatal PE recurrences (12 vs. 6 deaths). After discontinuing anticoagulation, the patients with asymptomatic SSPE had a similar rate of PE recurrences (HR: 1.27; 95% CI: 0.20–4.55) and a non-significantly higher mortality rate (HR: 2.06; 95% CI: 0.92–4.10). The patients with asymptomatic SSPE had similar rates of PE recurrences to those with symptomatic SSPE, during and after discontinuing anticoagulation. The unexpectedly higher rate of major bleeding than recurrences highlights the need for randomized trials to find the best management.

Published
2023
Full Text
View/download PDF

7. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

Author

Cohen, Yael C., Zada, Mor, Wang, Shuang-Yin, Bornstein, Chamutal, David, Eyal, Moshe, Adi, Li, Baoguo, Shlomi-Loubaton, Shir, Gatt, Moshe E., Gur, Chamutal, Lavi, Noa, Ganzel, Chezi, Luttwak, Efrat, Chubar, Evgeni, Rouvio, Ory, Vaxman, Iuliana, Pasvolsky, Oren, Ballan, Mouna, Tadmor, Tamar, Nemets, Anatoly, Jarchowcky-Dolberg, Osnat, Shvetz, Olga, Laiba, Meirav, Shpilberg, Ofer, Dally, Najib, Avivi, Irit, Weiner, Assaf, and Amit, Ido

Published
2021
Full Text
View/download PDF

8. Efficacy and safety of Apixaban in the treatment of cerebral venous sinus thrombosis: a multi-center study.

Author

Simaan, Naaem, Metanis, Issa, Honig, Asaf, Hallevi, Hen, Filioglo, Andrei, Mendel, Rom, Barnea, Rani, Naftali, Jonathan, Auriel, Eitan, Aladdin, Shorooq, Orion, David, Dally, Najib, Leker, Ronen R., and Molad, Jeremy

Subjects
CRANIAL sinuses, VENOUS thrombosis, SINUS thrombosis, ANTICOAGULANTS, APIXABAN, ORAL medication
Abstract

Background: Information regarding the safety and efficacy of specific direct oral anticoagulants (DOAC) in the treatment of cerebral sinus and venous thrombosis (CSVT) is scarce. Apixaban is one of the most frequently prescribed DOACs. Therefore, we aimed to compare the safety and efficacy of Apixaban with those of vitamin k antagonists (VKA) in patients with CSVT. Methods: Prospective CSVT databases from seven academic medical centers were retrospectively analyzed. Patients treated with Apixaban were compared to those treated with VKA. Data on demographics, clinical presentations, risk factors, radiological and outcome parameters were studied. Results: Overall, 403 patients were included in the analysis. Of them, 48 (12%) were treated with Apixaban, and 355 (88%) were treated with VKA. Rates of coagulopathies were significantly higher in the VKA-treated patients but no other differences between the groups were found in baseline characteristics and underlying etiology. No significant differences were found between groups in efficacy or safety parameters including the rates of recanalization, favorable outcomes, one-year mortality, seizures, intracranial hemorrhage or CSVT recurrences. Conclusion: Our data suggests that Apixaban may be safe and effective for patients with CSVT. These results should be tested in prospective randomized clinical studies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level

Author

Haring, Yael, primary, Goldschmidt, Noa, additional, Taha, Shaimaa, additional, Stemer, Galia, additional, Filanovsky, Kalman, additional, Hellman, Ilana, additional, Okasha, Doaa, additional, Krayem, Baher, additional, Levi, Itai, additional, Rosenbaum, Hanna, additional, Koren-Michowitz, Maya, additional, Yagna, Shai, additional, Nemets, Anatoly, additional, Gino-Moor, Sharon, additional, Saban, Revital, additional, Cohen, Joseph, additional, Halperin, Erez, additional, Wolach, Ofir, additional, Dally, Najib, additional, Merkel, Drorit, additional, Oster, Howard S., additional, and Mittelman, Moshe, additional

Published
2023
Full Text
View/download PDF

13. P651: REAL-WORLD EFFECTIVENESS OF VENETOCLAX-BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN ISRAEL: UPDATE FROM THE MULTICENTER PROSPECTIVE REVEAL STUDY

Author

Herishanu, Yair, primary, Goldschmidt, Neta, additional, Itchaki, Gilad, additional, Bronstein, Yotam, additional, Levi, Itai, additional, Aviv, Ariel, additional, Fineman, Riva, additional, Dally, Najib, additional, Tadmor, Tamar, additional, Ronson, Aaron, additional, Abadi, Uri, additional, Shvidel, Levi, additional, Stemer, Galia, additional, Kay, Sigi, additional, Glait Santar, Chen, additional, Barak, Moran, additional, Rivlin, Noa, additional, Kaminsky, Natalie, additional, Cohen, Raanan, additional, Ofek, Keren, additional, Berelovich, Jenia, additional, Grunspan, Moshe, additional, and Benjamini, Ohad, additional

Published
2023
Full Text
View/download PDF

15. Higher Infection Rate After 7- Compared With 5-Day Cycle of Azacitidine in Patients With Higher-Risk Myelodysplastic Syndrome

Author

Ofran, Yishai, Filanovsky, Kalman, Gafter-Gvili, Anat, Vidal, Liat, Aviv, Ariel, Gatt, Moshe E., Silbershatz, Itay, Herishanu, Yair, Arad, Ariela, Tadmor, Tamar, Dally, Najib, Nemets, Anatoly, Rouvio, Ory, Ronson, Aharon, Herzog-Tzarfati, Katrin, Akria, Luiza, Braester, Andrei, Hellmann, Ilana, Yeganeh, Shay, Nagler, Arnon, Leiba, Ronit, Mittelman, Moshe, and Merkel, Drorit

Published
2015
Full Text
View/download PDF

16. Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

Author

Stemer, Galia, primary, Wolach, Ofir, additional, Levi, Itai, additional, Nachmias, Boaz, additional, Tavor, Sigal, additional, Canaani, Jonathan, additional, Ofran, Yishai, additional, Ganzel, Chezi, additional, Zuckerman, Tsila, additional, Okasha, Doaa, additional, Hellmann, Ilana, additional, Tadmor, Tamar, additional, Dally, Najib, additional, Cohen, Raanan, additional, Berelovich, Jenia, additional, Ofek, Keren, additional, Rivlin, Noa, additional, Frankel, Neta, additional, Grunspan, Moshe, additional, and Moshe, Yakir, additional

Published
2022
Full Text
View/download PDF

18. Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Author

Cohen, Yael C, primary, Gatt, Moshe E, additional, Luttwak, Efrat, additional, Lavi, Noa, additional, Ganzel, Chezi, additional, Chubar, Evgeni, additional, Rouvio, Ory, additional, Vaxman, Iuliana, additional, Pasvolsky, Oren, additional, Ballan, Mouna, additional, Tadmor, Tamar, additional, Nemets, Anatoly, additional, Jarchowsky, Osnat, additional, Shvetz, Olga, additional, Shpilberg, Ofer, additional, Dally, Najib, additional, Leiba, Merav, additional, Weiner, Assaf, additional, Zada, Mor, additional, Wang, Shuang-Yin, additional, Gur, Chamutal, additional, Lowenton-Spier, Noa, additional, Goor-Porges, Liron, additional, Amit, Ido, additional, and Avivi, Irit, additional

Published
2022
Full Text
View/download PDF

19. Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Author

Ganzel, Chezi, primary, Moshe, Yakir, additional, Levi, Itai, additional, Nachmias, Boaz, additional, Tavor, Sigal, additional, Canaani, Jonathan, additional, Zuckerman, Tsila, additional, Okasha, Doaa, additional, Hellmann, Ilana, additional, Tadmor, Tamar, additional, Dally, Najib, additional, Stemer, Galia, additional, Cohen, Raanan, additional, Berelovich, Jenia, additional, Rivlin, Noa, additional, Frankel, Neta, additional, Grunspan, Moshe, additional, Ofek, Keren, additional, Ofran, Yishai, additional, and Wolach, Ofir, additional

Published
2022
Full Text
View/download PDF

21. Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study

Author

Herishanu, Yair, primary, Goldschmidt, Neta, additional, Itchaki, Gilad, additional, Levi, Itai, additional, Aviv, Ariel, additional, Fineman, Riva, additional, Dally, Najib, additional, Tadmor, Tamar, additional, Ruchlemer, Rosa, additional, Abadi, Uri, additional, Shvidel, Lev, additional, Braester, Andrei, additional, Cohen, Raanan, additional, Frankel, Neta, additional, Ofek, Keren, additional, Berelovich, Jenia, additional, Grunspan, Moshe, additional, and Benjamini, Ohad, additional

Published
2021
Full Text
View/download PDF

22. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR/ABL1 and its resistance and compound mutants BCR/ABL1T315I and BCR/ABL1T315I-E255K

Author

Ricardo M. Biondi, Claudia Chiriches, Elizabeh Eshel, Oliver G. Ottmann, Larissa Pietsch, Dally Najib, Isabella Haberbosch, Martin Ruthardt, Oliver Hantschel, Abed Agbarya, Jamal Mahajna, Afsar Ali Mian, and Hazem Khamaisie

Subjects
kinase, domain, Allosteric regulation, philadelphia chromosome-positive leukemia, allosteric inhibition, bcr, tki resistance, chemistry.chemical_compound, hemic and lymphatic diseases, site, medicine, ROS1, crizotinib, ABL, Crizotinib, Chemistry, Ponatinib, breakpoint cluster region, Hematology, General Medicine, mutations, medicine.disease, Leukemia, bcr-abl1, Cancer research, compound mutations, Tyrosine kinase, medicine.drug
Abstract

Resistance remains the major clinical challenge for the therapy of Philadelphia chromosome–positive (Ph+) leukemia. With the exception of ponatinib, all approved tyrosine kinase inhibitors (TKIs) are unable to inhibit the common “gatekeeper” mutation T315I. Here we investigated the therapeutic potential of crizotinib, a TKI approved for targeting ALK and ROS1 in non-small cell lung cancer patients, which inhibited also the ABL1 kinase in cell-free systems, for the treatment of advanced and therapy-resistant Ph+ leukemia. By inhibiting the BCR-ABL1 kinase, crizotinib efficiently suppressed growth of Ph+ cells without affecting growth of Ph− cells. It was also active in Ph+ patient-derived long-term cultures (PD-LTCs) independently of the responsiveness/resistance to other TKIs. The efficacy of crizotinib was confirmed in vivo in syngeneic mouse models of BCR-ABL1- or BCR-ABL1T315I-driven chronic myeloid leukemia–like disease and in BCR-ABL1-driven acute lymphoblastic leukemia (ALL). Although crizotinib binds to the ATP-binding site, it also allosterically affected the myristol binding pocket, the binding site of GNF2 and asciminib (former ABL001). Therefore, crizotinib has a seemingly unique double mechanism of action, on the ATP-binding site and on the myristoylation binding pocket. These findings strongly suggest the clinical evaluation of crizotinib for the treatment of advanced and therapy-resistant Ph+ leukemia.

Published
2021

24. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Author

Benjamini, Ohad, primary, Rokach, Lior, additional, Itchaki, Gilad, additional, Braester, Andrei, additional, Shvidel, Lev, additional, Goldschmidt, Neta, additional, Shapira, Shirley, additional, Dally, Najib, additional, Avigdor, Abraham, additional, Rahav, Galia, additional, Lustig, Yaniv, additional, Ben David, Shirley Shapiro, additional, Fineman, Riva, additional, Paz, Alona, additional, Bairey, Osnat, additional, Polliack, Aaron, additional, Levy, Ilana, additional, and Tadmor, Tamar, additional

Published
2021
Full Text
View/download PDF

27. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1

Author

Afsar Ali, Mian, Isabella, Haberbosch, Hazem, Khamaisie, Abed, Agbarya, Larissa, Pietsch, Elizabeh, Eshel, Dally, Najib, Claudia, Chiriches, Oliver Gerhard, Ottmann, Oliver, Hantschel, Ricardo M, Biondi, Martin, Ruthardt, and Jamal, Mahajna

Subjects
TKI resistance, Fusion Proteins, bcr-abl, Antineoplastic Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma, BCR-ABL1, Philadelphia chromosome–positive leukemia, Jurkat Cells, Mice, Adenosine Triphosphate, Allosteric inhibition, Allosteric Regulation, Crizotinib, Drug Resistance, Neoplasm, hemic and lymphatic diseases, Cell Line, Tumor, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mutation, Compound mutations, Animals, Humans, Original Article, Proto-Oncogene Proteins c-abl, Protein Kinase Inhibitors
Abstract

Resistance remains the major clinical challenge for the therapy of Philadelphia chromosome–positive (Ph+) leukemia. With the exception of ponatinib, all approved tyrosine kinase inhibitors (TKIs) are unable to inhibit the common “gatekeeper” mutation T315I. Here we investigated the therapeutic potential of crizotinib, a TKI approved for targeting ALK and ROS1 in non-small cell lung cancer patients, which inhibited also the ABL1 kinase in cell-free systems, for the treatment of advanced and therapy-resistant Ph+ leukemia. By inhibiting the BCR-ABL1 kinase, crizotinib efficiently suppressed growth of Ph+ cells without affecting growth of Ph− cells. It was also active in Ph+ patient-derived long-term cultures (PD-LTCs) independently of the responsiveness/resistance to other TKIs. The efficacy of crizotinib was confirmed in vivo in syngeneic mouse models of BCR-ABL1- or BCR-ABL1T315I-driven chronic myeloid leukemia–like disease and in BCR-ABL1-driven acute lymphoblastic leukemia (ALL). Although crizotinib binds to the ATP-binding site, it also allosterically affected the myristol binding pocket, the binding site of GNF2 and asciminib (former ABL001). Therefore, crizotinib has a seemingly unique double mechanism of action, on the ATP-binding site and on the myristoylation binding pocket. These findings strongly suggest the clinical evaluation of crizotinib for the treatment of advanced and therapy-resistant Ph+ leukemia.

Published
2020

28. Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapy

Author

Barki-Harrington, Liza, primary, Baron-Epel, Orna, additional, Shaulov, Adir, additional, Akria, Luiza, additional, Barshay, Yossef, additional, Dally, Najib, additional, Deshet, Dana, additional, Inbar, Tsofia, additional, Koren-Michowitz, Maya, additional, Leiba, Merav, additional, Moshe, Yakir, additional, Shvidel, Lev, additional, Tadmor, Tamar, additional, Yagenah, Shai, additional, Zektser, Miri, additional, Preis, Meir, additional, Hellman, Ilana, additional, Yahalom, Vered, additional, and Aviv, Ariel, additional

Published
2021
Full Text
View/download PDF

29. Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data from the Israeli MPN Working Group

Author

Gutwein, Odit, primary, Lavi, Noa, additional, Barzilai, Merav, additional, Shacham-Abulafia, Adi, additional, Leader, Avi, additional, Chubar, Evgeni, additional, Dally, Najib, additional, Shapira, Shirley, additional, Mishchenko, Elena, additional, Ellis, Martin, additional, and Koren-Michowitz, Maya, additional

Published
2020
Full Text
View/download PDF

31. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: Aretrospective multicenter study

Author

Merkel, Drorit, Filanovsky, Kalman, Gafter-Gvili, Anat, Vidal, Liat, Aviv, Ariel, Gatt, Moshe E., Silbershatz, Itay, Herishanu, Yair, Arad, Ariela, Tadmor, Tamar, Dally, Najib, Nemets, Anatoly, Rouvio, Ory, Ronson, Aharon, Herzog-Tzarfati, Katrin, Akria, Luiza, Braester, Andrei, Hellmann, Ilana, Yeganeh, Shay, Nagler, Arnon, Leiba, Ronit, Mittelman, Moshe, and Ofran, Yishai

Published
2013
Full Text
View/download PDF

33. Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Author

Segman, Yafit, primary, Ribakovsky, Elena, additional, Avigdor, Abraham, additional, Vainstein, Vladimir, additional, Goldschmidt, Neta, additional, Harlev, Shimrit Ringelstein, additional, Gutwein, Odit, additional, Abadi, Uri, additional, Nemets, Anatoly, additional, Sofer, Orit, additional, Dally, Najib, additional, Filanovsky, Kalman, additional, Leiba, Merav, additional, Sarid, Nadav, additional, Benyamini, Noam, additional, Herishanu, Yair, additional, Ram, Ron, additional, Perry, Chava, additional, and Avivi, Irit, additional

Published
2019
Full Text
View/download PDF

35. A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chain

Author

Tamar Tadmor, Yair Herishanu, Andrei Braester, Kelly Townsend, Aaron Polliack, Clara Henig, Lev Shvidel, Naomi Rahimi-Levene, Mona Yuklea, Ariela Arad, Mira Barak, Claudia Fogl, Lee Magal, Rosa Ruchlemer, Ariel Aviv, and Dally Najib

Subjects
Oncology, Male, medicine.medical_specialty, Multivariate analysis, Chronic lymphocytic leukemia, medicine.disease_cause, Subclass, Time-to-Treatment, Risk model, Internal medicine, Medicine, Humans, Prospective cohort study, Aged, Proportional Hazards Models, Aged, 80 and over, business.industry, Time to first treatment, Hazard ratio, Hematology, General Medicine, Immune dysregulation, Middle Aged, Models, Theoretical, medicine.disease, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell, Female, Immunoglobulin Light Chains, business, Immunoglobulin Heavy Chains, Biomarkers
Abstract

BACKGROUND Chronic lymphocytic leukemia (CLL) is frequently accompanied by immune dysregulation. AIMS In this multicenter prospective study, we investigated whether heavy + light chains (HLC: IgGκ, IgGλ, IgAκ, IgAκ, IgMκ, IgMλ) and IgG subclasses (IgG1, IgG2, IgG3, and IgG4) could be used as novel prognostic markers of immunoparesis in 105 treatment-naive patients with CLL. RESULTS Heavy + light chains immunoparesis of ≥1, ≥2, and ≥3 isotypes was evident in 74 (70%), 58 (55%), and 36 (34%) patients, respectively. Severe HLC immunoparesis was identified in 40 (38%) patients. Of the IgG subclasses, IgG1 and IgG2 were most frequently suppressed, affecting 46 (44%) and 36 (34%) patients, respectively; 63 (60%) patients had low levels of at least one IgG subclass. In multivariate analysis, severe HLC immunoparesis (hazard ratio [HR]: 36.5; P = .010) and ΣFLC ≥ 70 mg/L (HR: 13.2; P = .004) were the only factors independently associated with time to first treatment (TTFT). A risk model including these variables identified patients with 0, 1, and 2 risk factors and significantly different TTFT (P

Published
2019

36. Non-immune Hemolysis in Gaucher Disease and Review of the Literature.

Author

Hershkop, Eliyakim, Bergman, Idan, Kurolap, Alina, Dally, Najib, and Feldman, Hagit Baris

Subjects
GAUCHER'S disease, AUTOIMMUNE hemolytic anemia, HEMOLYTIC anemia, HEMOLYSIS & hemolysins, LITERATURE reviews
Abstract

Gaucher disease (GD) is an autosomal recessive disease characterized by the buildup of glucocerebrosides in macrophages, resulting in the formation of "Gaucher cells." These cells predominantly infiltrate the liver, spleen, and bone marrow leading to hepatosplenomegaly, cytopenia, and bone pain. Anemia in GD is typically considered to result from non-hemolytic processes. Although rare, a higher rate of hemolytic anemia of the autoimmune type has been reported in GD than in the general population. The literature on non-immune hemolytic anemia in GD is scarce. We review the literature on hemolytic anemia in GD and report on a case of non-immune hemolytic anemia secondary to GD. We believe this is the first description of a patient with confirmed GD and symptomatic non-immune hemolytic anemia that responded to GD-specific treatment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

37. Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data from the Israeli MPN Working Group.

Author

Gutwein, Odit, Lavi, Noa, Barzilai, Merav, Shacham-Abulafia, Adi, Leader, Avi, Chubar, Evgeni, Dally, Najib, Shapira, Shirley, Mishchenko, Elena, Ellis, Martin, and Koren-Michowitz, Maya

Subjects
VENOUS thrombosis, FIBRINOLYTIC agents, PHOSPHOLIPID antibodies, TUMORS, OLDER patients, ACTIVATED protein C resistance
Abstract

The BCR-ABL-negative myeloproliferative neoplasms (MPN) are associated with high incidence of venous thrombosis and a significant rate of recurrent events, but there is no consensus regarding their management. In this retrospective study, we analyzed 96 patients with MPN-related venous thrombosis. The index venous thrombosis occurred at a median age of 58 years (IQR 37–71), with 58% of the events involving unusual sites. Patients who were on antiplatelet agents at the time of index thrombosis tended to be older than patients who were not receiving antiplatelets at the time of index thrombosis. The majority of index thromboses occurring after the diagnosis of MPN had uncontrolled blood counts at the time of event and were not receiving antithrombotic agents. Following the thrombotic episode, 75% of patients received long-term anticoagulation. At a median follow-up of 3.4 years, the recurrence rate was 14%. Thrombophilia was significantly more prevalent among patients with recurrent thrombosis compared to patients without recurrence (p < 0.01). Patients who developed a recurrent event early were more likely to have thrombophilia (either inherited or antiphospholipid antibodies), and controlled blood counts, and were likely to receive anticoagulation at the time of recurrence compared to patients with later recurrences. Thrombophilia may contribute to venous thrombosis recurrence, especially early after the index venous thrombosis. Suboptimal anticoagulation and blood count control are factors associated with late venous thrombosis recurrence. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

38. Rare Aggressive Form of Multiple Myeloma with Diffuse Osteosclerosis and Elevated CA 15-3 Levels

Author

Raymond Farah, Daniel Talmud, Rola Khamisy-Farah, Dally Najib, and Saher Srour

Subjects
Pathology, medicine.medical_specialty, Pleural effusion, business.industry, CA 15-3, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, medicine.disease, Organomegaly, Tumor lysis syndrome, 03 medical and health sciences, Osteosclerosis, 0302 clinical medicine, medicine, medicine.symptom, business, Polyneuropathy, Multiple myeloma, POEMS syndrome
Abstract

We report the case of a 56-year-old female who had recently been examined for back and epigastric pain, and was diagnosed in the internal medicine ward as having an aggressive rare form of multiple myeloma with diffuse osteoblastic bone lesions. She also had high levels of breast tumor marker (CA 15-3), severe tumor lysis syndrome, and pleural and central nervous system involvement. A few cases of multiple myeloma with diffuse osteosclerosis that are not part of POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changeshave) have been described. None of these cases were as aggressive as our case. To our knowledge it is the first report describing an elevation in CA 15-3 in conjunction with multiple myeloma.

Published
2016

39. Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in Israel

Author

Andrei Braester, Lev Shvidel, Uri Greenbaum, Adir Shaulov, Mona Yuklea, Aaron Polliack, Rosa Ruchlemer, Ory Rouvio, Tamar Tadmor, Osnat Bairey, Yair Herishanu, Neta Goldschmidt, Michal Inbar, Dally Najib, Riva Fineman, and Ariel Aviv

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Injections, Subcutaneous, Antineoplastic Agents, Demographic data, Time-to-Treatment, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Interquartile range, Internal medicine, medicine, Retrospective analysis, Humans, Hairy cell leukemia, Israel, Cladribine, Early Detection of Cancer, Aged, Retrospective Studies, Aged, 80 and over, Univariate analysis, Leukemia, Hairy Cell, business.industry, Retrospective cohort study, General Medicine, Middle Aged, medicine.disease, Survival Analysis, Ashkenazi jews, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Administration, Intravenous, Female, business, 030215 immunology, medicine.drug
Abstract

Background/aim In this retrospective study, we summarized the national Israeli experience with hairy cell leukemia (HCL) in a large cohort of patients with a long follow-up. Patients and methods Demographic data, and relevant laboratory and clinical parameters were analyzed, emphasizing the outcome after first-line treatment with cladribine. Results Data on 203 patients was collected from 12 medical centers during 1985-2015. Mean and median follow-up were 7.5 years and 5.18 years (interquartile range=0.1-40 years), and 5- and 10-year survival were 96% and 90.62%, respectively. The median age of diagnosis was 55.5 years for Jews and 49 years for Arabs (p=0.021), and most patients were males (81.77%); 52.2% were Ashkenazi Jews, 36.1% Sephardic Jews and 11.7% were Arab, Druze or other ethnicity. Cladribine was given to 159 patients (80.7%%) and most (62%) received intravenous (i.v.) and 38% received subcutaneous (s.c.) therapy. Overall survival and time to next treatment were not significantly different between the two schedules (i.v., s.c.). In univariate analysis of a variety of factors, only age >65 years had a negative impact on outcome, with shorter overall survival. It is of interest that Arab patients with HCL were diagnosed at an earlier age, but had a similar clinical course and outcome to both Ashkenazi and Sephardic Jews.

Published
2018

42. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Author

Dimopoulos, Meletios A, primary, Gay, Francesca, additional, Schjesvold, Fredrik, additional, Beksac, Meral, additional, Hajek, Roman, additional, Weisel, Katja Christina, additional, Goldschmidt, Hartmut, additional, Maisnar, Vladimir, additional, Moreau, Philippe, additional, Min, Chang Ki, additional, Pluta, Agnieszka, additional, Chng, Wee-Joo, additional, Kaiser, Martin, additional, Zweegman, Sonja, additional, Mateos, Maria-Victoria, additional, Spencer, Andrew, additional, Iida, Shinsuke, additional, Morgan, Gareth, additional, Suryanarayan, Kaveri, additional, Teng, Zhaoyang, additional, Skacel, Tomas, additional, Palumbo, Antonio, additional, Dash, Ajeeta B, additional, Gupta, Neeraj, additional, Labotka, Richard, additional, Rajkumar, S Vincent, additional, Bar, Daniel, additional, Basso, Alfredo, additional, Fantl, Dorotea, additional, He, Simon, additional, Horvath, Neomi, additional, Lee, Cindy, additional, Rowlings, Phillip, additional, Taylor, Kerry, additional, Cochrane, Tara, additional, Kwok, Fiona, additional, Ramanathan, Sundreswran, additional, Agis, Hermine, additional, Zojer, Niklas, additional, Kentos, Alain, additional, Offner, Fritz, additional, Van Droogenbroeck, Jan, additional, Wu, Ka Lung, additional, Maiolino, Angelo, additional, Martinez, Gracia, additional, Zanella, Karla, additional, Capra, Marcelo, additional, Araújo, Sérgio, additional, Gregora, Evzen, additional, Pour, Ludek, additional, Scudla, Vlastimil, additional, Spicka, Ivan, additional, Abildgaard, Niels, additional, Andersen, Niels, additional, Jensen, Bo Amdi, additional, Helleberg, Carsten, additional, Plesner, Torben, additional, Salomo, Morten, additional, Svirskaite, Asta, additional, Delarue, Richard, additional, Blau, Igor, additional, Schieferdecker, Aneta, additional, Teleanu, Veronica, additional, Munder, Markus, additional, Röllig, Christoph, additional, Salwender, Han-Juergen, additional, Fuhrmann, Stephan, additional, Weisel, Katja, additional, Duerig, Jan, additional, Zeis, Matthias, additional, Klein, Stefan, additional, Reimer, Peter, additional, Schmidt, Christian, additional, Scheid, Christof, additional, Mayer, Karin, additional, Hoffmann, Martin, additional, Sosada, Markus, additional, Dimopoulos, Athanasios, additional, Delimpasi, Sosana, additional, Kyrtsonis, Mary-Christine, additional, Anagnostopoulos, Achilleas, additional, Nagy, Zsolt, additional, Illés, Árpád, additional, Egyed, Miklós, additional, Borbényi, Zita, additional, Mikala, Gabor, additional, Dally, Najib, additional, Horowitz, Netanel, additional, Gutwein, Odit, additional, Nemets, Anatoly, additional, Vaxman, Iuliana, additional, Shvetz, Olga, additional, Trestman, Svetlana, additional, Ruchlemer, Rosa, additional, Nagler, Arnon, additional, Tadmor, Tamar, additional, Rouvio, Ory, additional, Preis, Meir, additional, Cavo, Michele, additional, De Rosa, Luca, additional, Musto, Pellegrino, additional, Cafro, Anna, additional, Tosi, Patrizia, additional, Offidani, Massimo, additional, Corso, Alessandro, additional, Rossi, Giuseppe, additional, Liberati, Anna Marina, additional, Bosi, Alberto, additional, Suzuki, Kenshi, additional, Nakaseko, Chiaki, additional, Ishikawa, Takayuki, additional, Matsumoto, Morio, additional, Nagai, Hirokazu, additional, Sunami, Kazutaka, additional, Chou, Takaaki, additional, Akashi, Koichi, additional, Takezako, Naoki, additional, Hagiwara, Shotaro, additional, Eom, Hyeon Seok, additional, Jo, Deog-Yeon, additional, Kim, Jin Seok, additional, Lee, Jae Hoon, additional, Yoon, Sung Soo, additional, Yoon, Dok Hyun, additional, Kim, Kihyun, additional, Levin, Mark-David, additional, Vellenga, Edo, additional, Minnema, Monique, additional, Waage, Anders, additional, Haukås, Einar, additional, Grosicki, Sebastian, additional, Pluta, Andrzej, additional, Robak, Tadeusz, additional, Marques, Herlander, additional, Bergantim, Rui, additional, Campilho, Fernando, additional, Chng, Wee Joo, additional, Goh, Yeow Tee, additional, McDonald, Andrew, additional, Rapoport, Bernado, additional, Álvarez Rivas, Miguel Angel, additional, De Arriba de La Fuente, Felipe, additional, González Montes, Yolanda, additional, Martin Sanchez, Jesus, additional, Mateos, Maria Victoria, additional, Oriol Rocafiguera, Albert, additional, Rosinol, Laura, additional, San Miguel, Jesús, additional, Pérez de Oteyza, Jaime, additional, Encinas, Cristina, additional, Alegre-Amor, Adrian, additional, López-Guía, Ana, additional, Axelsson, Per, additional, Carlson, Kristina, additional, Stromberg, Olga, additional, Hansson, Markus, additional, Hveding Blimark, Cecile, additional, Mueller, Rouven, additional, Chen, Chih-Cheng, additional, Liu, Ta-Chih, additional, Huang, Shang-Yi, additional, Wang, Po-Nan, additional, Na Nakorn, Thanyaphong, additional, Prayongratana, Kannadit, additional, Unal, Ali, additional, Goker, Hakan, additional, Sonmez, Mehmet, additional, Korenkova, Sybiryna, additional, Chaidos, Aristeidis, additional, Oakervee, Heather, additional, Sati, Hamdi, additional, Benjamin, Reuben, additional, Wechalekar, Ashutosh, additional, Garg, Mamta, additional, Ramasamy, Karthik, additional, Cook, Gordon, additional, Chantry, Andrew, additional, Jenner, Matthew, additional, Buadi, Francis, additional, Berryman, Robert, additional, and Janakiram, Murali, additional

Published
2019
Full Text
View/download PDF

43. Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience

Author

Benyamini, Noam, primary, S, Adir, additional, Gatt, Moshe E., additional, Cohen, Yael C, additional, Avivi, Irit, additional, Trestman, Svetlana, additional, Shvetz, Olga, additional, Tadmor, Tamar, additional, Dally, Najib, additional, Chober, Yevgeny, additional, Magen, Hila, additional, Ganzel, Chezi, additional, Jarchowcky Dolberg, Osnat, additional, Suriu, Celia, additional, and Lavi, Noa, additional

Published
2018
Full Text
View/download PDF

44. A Novel Risk-Model to Predict Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia Based on Heavy+Light Chain Immunoparesis and Serum Free Light Chain Analysis: Results from the Israeli CLL Study Group

Author

Tadmor, Tamar, primary, Braester, Andrei, additional, Dally, Najib, additional, Aviv, Ariel, additional, Herishanu, Yair, additional, Yuklea, Mona, additional, Shvidel, Lev, additional, Rahimi-Levene, Naomi, additional, Ruchlemer, Rosa, additional, Arad, Ariela, additional, Fogl, Claudia, additional, Polliack, Aaron, additional, Magal, Lee, additional, and Townsend, Kelly, additional

Published
2018
Full Text
View/download PDF

45. Leukocyte alkaline phosphatase (LAP) by flow cytometry

Author

Eshel, Elizabeth, Sharabi-Nov, Adi, and Dally, Najib

Subjects
Flow cytometry -- Usage -- Health aspects, Phosphatases -- Research, Chronic myeloid leukemia -- Research -- Diagnosis, Business, Health care industry
Abstract

Introduction A Leukocyte Alkaline Phosphatase (LAP) score is still requested from the hematology laboratory as an aid in differential diagnosis in the peripheral hospital setting where molecular biology techniques are [...]

Published
2013

46. The neutrophil/lymphocyte ratio is a better addition to C-reactive protein than CD64 index as a marker for infection in COPD

Author

Dally Najib, Raymond Farah, Rabia Ibrahim, Majd Nassar, Yifat Zivony, and Elizabeth Eshel

Subjects
Erythrocyte Indices, Male, Time Factors, Exacerbation, Neutrophils, 030204 cardiovascular system & hematology, Severity of Illness Index, Gastroenterology, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Lymphocytes, Prospective Studies, Prospective cohort study, Respiratory Tract Infections, Aged, 80 and over, COPD, medicine.diagnostic_test, biology, Complete blood count, General Medicine, Middle Aged, C-Reactive Protein, Area Under Curve, Disease Progression, Female, Inflammation Mediators, Mean Platelet Volume, Adult, medicine.medical_specialty, 03 medical and health sciences, Predictive Value of Tests, Internal medicine, medicine, Humans, Lymphocyte Count, Mean platelet volume, Aged, business.industry, Receptors, IgG, fungi, C-reactive protein, Case-control study, Reproducibility of Results, Red blood cell distribution width, medicine.disease, respiratory tract diseases, ROC Curve, 030228 respiratory system, Case-Control Studies, Immunology, biology.protein, business, Biomarkers
Abstract

BACKGROUND This study investigated the importance of neutrophil/lymphocyte ratio (NLR) and other new inflammatory markers including CD64 expression in patients with chronic obstructive pulmonary disease (COPD) for identifying the severity of inflammation and recognition of acute exacerbation and infection. METHODS Seventy-two patients with a diagnosis of COPD exacerbation who were admitted to the Department of Internal Medicine B, 13 with stable COPD, and control group of 15 healthy people were enrolled in the study. Complete blood count (CBC), measurement of C-reactive protein (CRP), mean platelet volume (MPV), red blood cell distribution width (RDW) and CD64 expression were determined within 2 hours of hospital admission. RESULTS NLR and other inflammatory markers, such as RDW, CRP, and CD64 were found to be significantly elevated in exacerbated COPD compared to stable COPD and control participants. There was a significant correlation of NLR with CRP (r=0.309, P

Published
2017

47. Treatment and prognosis of stage I follicular lymphoma in the modern era – does PET matter?

Author

Bentur, Ohad S., primary, Gurion, Ronit, additional, Gafter-Gvili, Anat, additional, Gatt, Moshe, additional, Shvidel, Lev, additional, Horowitz, Netanel A., additional, Ram, Ron, additional, Herishanu, Yair, additional, Sarid, Nadav, additional, Paltiel, Ora, additional, Ganzel, Chezi, additional, Kreiniz, Natalia, additional, Dally, Najib, additional, Gutwein, Odit, additional, Raanani, Pia, additional, Avivi, Irit, additional, and Perry, Chava, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results